Drugs / SGR-3515
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06463340 | Jun 2024 → Oct 2026 expected | — | Schrödinger, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Schrödinger, Inc. | Results Schrödinger Presents New Preclinical Data at AACR Annual Meeting schrodinger.com ↗
The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. |
| 2024-10-23 | Schrödinger, Inc. | Results Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium schrodinger.com ↗
The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. |
| 2024-05-01 | Schrödinger, Inc. | Regulatory Schrödinger Reports First Quarter 2024 Financial Results schrodinger.com ↗
Today we reported FDA clearance of our IND application for SGR-3515, our novel Wee1/Myt1 inhibitor, and expect to initiate a Phase 1 clinical study in patients with solid tumors this year. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Schrödinger, Inc. | Schrödinger Presents New Preclinical Data at AACR Annual Meeting schrodinger.com ↗ |
| 2024-10-23 | Schrödinger, Inc. | Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium schrodinger.com ↗ |
| 2024-10-09 | Schrödinger, Inc. | Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium schrodinger.com ↗ |
| 2024-05-01 | Schrödinger, Inc. | Schrödinger Reports First Quarter 2024 Financial Results schrodinger.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGR-3515 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06463340 ↗ |
| Route | Oral | “SGR-3515 will be administered orally with an intermittent schedule.” NCT06463340 ↗ |